載入中
Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides three next generation antibody drug conjugates (ADC) portfolio to treat cancer. The company was formerly known as Aadi Bioscience, Inc. and changed its name to Whitehawk Therapeutics, Inc. in August 2021. Whitehawk Therapeutics, Inc. was incorporated in 2007 and is headquartered in Morristown, New Jersey.
收盤時
US$3.02
−US$0.36 · -10.65%
盤後
US$3.06
+US$0.04 · +1.32%
10月13日 下午7:30 ET
盤中時間採用ET。市場資料可能有所延遲。
Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides three next generation antibody drug conjugates (ADC) portfolio to treat cancer. The company was formerly known as Aadi Bioscience, Inc. and changed its name to Whitehawk Therapeutics, Inc. in August 2021. Whitehawk Therapeutics, Inc. was incorporated in 2007 and is headquartered in Morristown, New Jersey.
日內區間
目前US$3.02
52週區間
目前US$3.02
盤中時間採用ET。市場資料可能有所延遲。
Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides three next generation antibody drug conjugates (ADC) portfolio to treat cancer. The company was formerly known as Aadi Bioscience, Inc. and changed its name to Whitehawk Therapeutics, Inc. in August 2021. Whitehawk Therapeutics, Inc. was incorporated in 2007 and is headquartered in Morristown, New Jersey.
日內區間
目前US$3.02
52週區間
目前US$3.02
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 714.5萬 USD | 2598.3萬 USD | 2435.4萬 USD | 1521.6萬 USD | 112萬 USD |
| 銷貨成本 | 76萬 USD | 5405.4萬 USD | 5173.8萬 USD | 3399.7萬 USD | 1967萬 USD |
| 毛利 | 638.5萬 USD | −2807.1萬 USD | −2738.4萬 USD | −1878.1萬 USD | −1855萬 USD |
| 研究與開發 | 9096.3萬 USD | 5103萬 USD | 4892.9萬 USD | 3266.2萬 USD | 1967萬 USD |
| 銷售、一般及管理費用 | 2982.2萬 USD | 3674.9萬 USD | 4454.9萬 USD | 4017.6萬 USD | 1851.1萬 USD |
| 營業費用 | 1.21億 USD | 3938.7萬 USD | 4454.9萬 USD | 4390萬 USD | 9266.7萬 USD |
| 利息收入 | 623.1萬 USD | 392.5萬 USD | 640萬 USD | 239.8萬 USD | 1.3萬 USD |
| 利息支出 | — | 15.4萬 USD | 23.1萬 USD | 23萬 USD | 66.5萬 USD |
| 折舊和攤銷 | 7.9萬 USD | 19.3萬 USD | 16.9萬 USD | 15.9萬 USD | 10.5萬 USD |
| 營業利益 | −1.14億 USD | −6745.8萬 USD | −7193.3萬 USD | −6268.1萬 USD | −1.11億 USD |
| 淨利 | −2059.6萬 USD | −6369.1萬 USD | −6576.5萬 USD | −6051.3萬 USD | −1.1億 USD |
公司資料更新於 2026年10月14日。
已公布業績及可用的市場共識預估。
已公布業績及可用的市場共識預估。
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI403.14萬0.00%2.3兆 USD0.03%US$381.32-0.07%
iShares Russell 2000 ETFIWM352.68萬0.00%787.4億 USD0.19%US$276.7-0.43%
Vanguard Extended Market ETFVXF204.23萬0.00%954億 USD0.05%US$232.54-0.42%
iShares Russell 2000 Value ETFIWN134.09萬0.01%137.49億 USD0.24%US$210.99-0.05%
Vanguard Russell 2000 ETFVTWO84.16萬0.00%180億 USD0.06%US$111.77-0.45%
iShares Micro-Cap ETFIWC45.89萬0.04%13.17億 USD0.60%US$179.6-1.13%
OneAscent Enhanced Small and Mid Cap ETFOASC21.46萬0.22%9795.69萬 USD1.38%US$34.21-0.58%
Avantis U.S. Small Cap Equity ETFAVSC21.2萬0.01%30.79億 USD0.25%US$70.06+0.13%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Value ETFIWNVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCOneAscent Enhanced Small and Mid Cap ETFOASCAvantis U.S. Small Cap Equity ETFAVSCAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
